Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-0217/S001 +/- pembrolizumab in advanced solid tumors
NCT05916248Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of mRNA-0217 in solid tumor (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Maximum Tolerated Dose or Dose-Limiting Toxicity, Percentage of Participants With Adverse Events up to 54 weeks and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
mRNA-0217
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05916248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05916248.